AC Immune SA
ACIU evidence brief
What we can confirm
- Market Cap:
- $274.4M
What it means
What to watch
Prepared research question
What matters most for ACIU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACIU
AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, with active clinical programs in Alzheimer's and Parkinson's disease.
Key risk: Clinical trial failure risk
Market Cap
$274.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 10 clinical trials for AC Immune SA.
AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, with active clinical programs in Alzheimer's and Parkinson's disease.
- AC Immune is advancing ACI-7104.056, an active immunotherapy for early-stage Parkinson's disease, with positive safety and immunogenicity data through week 100 in Part 1 of the VacSYn Phase 2 trial [news · published 2026-09-23].
- The company reported favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inflammasome inhibitor, showing strong safety and brain penetration [news · published 2026-08-20].
- Interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease showed the drug was generally safe and well tolerated in the first three cohorts [news · published 2026-06-30].
- AC Immune maintains disciplined cost control with a cash runway extending into 4Q27, minimizing near-term financing risk [news · published 2026-07-02].
- The company is sharpening its focused investment on its most important programs following a strategic review by executive management [sec · filed 2025-09-04].
What works
- Positive long-term safety and immunogenicity data through week 100 for ACI-7104.056 in Parkinson's disease supports continued development [news · published 2026-09-23].
- Favorable early Phase 1 results for ACI-19764, an oral NLRP3 inhibitor, demonstrate strong safety and brain penetration, expanding the pipeline [news · published 2026-08-20].
- Disciplined cost control provides a cash runway into 4Q27, reducing near-term financing risk [news · published 2026-07-02].
What to weigh
- The company's pipeline is heavily reliant on a few key programs, with any clinical setback potentially impacting overall valuation [sec · filed 2025-09-04].
- As a clinical-stage company without approved products, AC Immune has no recurring revenue from product sales and depends on partnership and financing [sec · filed 2025-09-04].
- The strategic review and sharpened focus may indicate prior resource allocation inefficiencies or the need to prioritize amid limited capital [sec · filed 2025-09-04].
From the filings
Quoted directly from source documents.
Positive safety and immunogenicity results through week 100 for ACI-7104.056 in Parkinson's disease
“AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part”
News · September 23, 2026
Favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor
“AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.”
News · August 20, 2026
Interim 12-month data from Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease
“AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of”
News · June 30, 2026
Cash runway extending into 4Q27
“AC Immune maintains disciplined cost control, with a cash runway extending into 4Q27, minimizing near-term financing risk.”
News · July 2, 2026
Risks & what to watch (3)›
Key risks
- Clinical trial failure risk — Reliance on a few key programs; any clinical setback could significantly impact company prospects [sec · filed 2025-09-04].
- No approved product revenue — As a clinical-stage company, AC Immune has no product sales revenue and depends on partnerships and financing [sec · filed 2025-09-04].
- Strategic prioritization pressure — Sharpened focus after strategic review suggests need to allocate limited capital efficiently [sec · filed 2025-09-04].
What to watch
- Final data from Part 1 of the VacSYn Phase 2 trial of ACI-7104.056 in early-stage Parkinson's disease [sec · filed 2026-02-17].
- Phase 1 trial results for ACI-19764, an NLRP3 inflammasome inhibitor, anticipated in the second half of 2026 [sec · filed 2026-02-17].
- Q4 2025 earnings results to be reported on March 12, 2026 [sec · filed 2026-02-17].
- Progress of the Phase 2b ReTain study (NCT06544616) for ACI-35.030/JNJ-2056 in Alzheimer's disease [sec · filed 2026-02-17].
Sources: Catalysts · News · SEC filings · Generated October 3, 2026 · How we verify sources →
Run AC Immune SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AC Immune SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$68.6M
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 19,822,436 | $54.5M |
| wells fargo & company/mn | 1,004,284 | $2.8M |
| millennium management llc | 792,657 | $2.2M |
| renaissance technologies llc | 624,367 | $1.7M |
| blackrock, inc. | 524,278 | $1.4M |
| arrowstreet capital, limited partnership | 405,658 | $1.1M |
| dimensional fund advisors lp | 390,165 | $1.1M |
| northern trust corp | 278,513 | $766K |
| citadel advisors llc | 267,233 | $735K |
| marshall wace, llp | 131,458 | $362K |
Showing top 10 of 46 institutional holders of AC Immune SA. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.2%
- Days to cover
- 11.6
- Shares short
- 3,034,113
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACIU short interestFrequently asked questions
What is the AI investment thesis for AC Immune SA?
AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, with active clinical programs in Alzheimer's and Parkinson's disease.
Who is the CEO of AC Immune SA?
Dr. Martin Zugel M.D., Ph.D. is the chief executive officer of AC Immune SA (ACIU).
Where is AC Immune SA headquartered?
AC Immune SA (ACIU) is headquartered in Lausanne, Switzerland.
What therapeutic areas does AC Immune SA focus on?
AC Immune SA develops therapies across Oncology, Neurology, Immunology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.